Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia by G. Gaidano et al.
American Journal of Pathology, Vol. 144, No. 6, June 1994
Copynight ©) American Societyfor Investigative Pathology
Analysis of Alterations of Oncogenes and Tumor
Suppressor Genes in Chronic Lymphocytic
Leukemia
Gianluca Gaidano,* Elizabeth W. Newcomb,t
Jerry Z. Gong,* Vittorio Tassi,* Antonino Neri,Y
Agostino Cortelezzi,t Rossella Calori,
Luca Baldini,t and Riccardo Dalla-Favera*
From the Division of Oncology, * Department ofPathology,
College ofPhysicians and Surgeons, Columbia University,
New York, New York; Department ofPathologyt and Kaplan
Cancer Center, New York University, New York, New York;
and Hematology Service,* Institute ofMedical Sciences,
Ospedale Maggiore I.R. C. C.S., Milan, Italy
B cell chronic lymphocytic leukemia (B-CLL) rep-
resents the mostfrequent adult leukemia in the
Western wordL The molecular pathogenesis of
B-CLL is largely unknown. Although initialreports
on smaUpanels ofcases had suggested a rolefor
Bcl-1 and Bcl-2 oncogene activation in B-CLL, later
investigations failed to confirm these data.
Among tumor suppressor genes, p53 mutations
have been reported in afraction ofcases. In this
study, we have attempted a conclusive definition
of the involvement of dominantly acting onco-
genes (Bcl-l and Bcl-2) andtumorsuppressor loci
(p53, 6q-) in 100 cases ofB-CLL selectedfor their
CD5 positivity and Rai's stage (0 to IV). Rear-
rangements of Bc-il and Bcl-2 and deletions of6q
and 17p were analyzed by Southern blot using
multiple probes. Mutational analysis (single
strand conformation polymorphism and polym-
erase chain reaction direct sequencing) was used
to assay p53 inactivation. No alterations of Bc-il
or Bc}2 were detected in the 100 cases tested. Mu-
tations ofp53 werefound in 10/100 cases without
any significant association with clinical stage. De-
letions of6q werepresent in 4/100 cases. Overall,
our data indicate that: 1) contrary to previous
reports, Bc-il and Bcl-2 rearrangements are not
involved in CD5+ B-CLL pathogenesis and 2)
p53 mutations are present in 10% of cases at aUl
stages of the disease. (Am J Pathol 1994,
144:1312-1319)
B cell chronic lymphocytic leukemia (B-CLL) is a ma-
lignancy of CD5+ B lymphocytes, a subpopulation of
B cells present at low levels in the normal adult. B-CLL
represents the most frequent type of all adult leuke-
mias in the Western world.1'2 Indeed, in some geo-
graphical areas, B-CLL accounts for up to 40% of
leukemias arising in the adult over 40 years of age.1' 2
The clinical course of B-CLL is highly variable, includ-
ing very indolent and rapid, aggressive forms that
may represent late stages of the disease or the trans-
formation of B-CLL into Richter's syndrome. The most
commonly used indicators of prognosis are the extent
and clinical features of the disease, classified accord-
ing to Rai's staging system, together with the kinetics
of proliferation of the neoplastic B lymphocyte
population.1-4 Other factors, ie, karyotypic abnor-
malities and immunophenotypic features, may also
have an independent prognostic value.1'2'5-7
The molecular pathogenesis of B-CLL is largely un-
known. Cytogenetic observations have revealed a
number of recurring chromosomal abnormalities, in-
cluding trisomy 12 and deletions involving band
13q14, the site of the RB1 gene, although the relevant
genes have not been identified.1' 2'56 The involve-
ment of dominantly acting oncogenes known to play
a role in B cell neoplasia, such as Bc/-i and Bcl-2, is
controversial. 1'269 Although initial studies suggested
a significant role for Bc1-i and Bcl-2 in B-CLL
pathogenesis, 10-16 their actual involvement has been
questioned by later investigations.17-20 Alterations of
other dominantly acting oncogenes, such as c-myc
and the ras family genes, have never been found in
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B-CLL. 17,18,21 Among tumor suppressor genes, we
and others have reported the presence of p53 inac-
tivation in a subset of B-CLL.22-24 The frequency of
this lesion appears to significantly increase on B-CLL
transformation into the aggressive lymphoma-like dis-
ease known as Richter's syndrome.22 Whether p53
mutations have any prognostic value in the course of
B-CLL and/or cluster with the advanced stages of
B-CLL (ie, Rai's stages Ill and IV) remains an open
question.
In this study we have analyzed a panel of 100
cases of B-CLL representing different stages of the
disease for a number of genetic lesions, including
rearrangements of the oncogenes Bc/-i and BcI-2,
inactivation of the tumor suppressor gene p53, and
deletions of 6q. The scope of the study was to con-
clusively define the frequency of each genetic lesion
in a large number of cases representing all stages of
disease and to investigate the associations between
genetic lesions and the clinical behavior of B-CLL.
Materials and Methods
Patients
Samples of peripheral blood (PB) were collected dur-
ing standard diagnostic procedures from 100 B-CLL
patients referred to the Hematology Service, Institute
of Medical Sciences, University of Milan, Italy. Diag-
nosis of B-CLL was according to the criteria of the
International Workshop on Chronic Lymphocytic Leu-
kemia and the National Cancer Institute-sponsored
Working Group, which included sustained lympho-
cytosis of greater than 10 x 1091/L in PB with mature
appearing lymphocytes and bone marrow (BM) lym-
phocytosis of at least 30% in BM aspirates.25'26 The
disease was staged according to Rai's staging sys-
tem.3 Lymphocyte doubling time (LDT) was calcu-
lated as previously reported.4 In all patients, the neo-
plastic lymphocytes co-expressed CD19 and CD5,
as demonstrated by immunophenotypic analysis of
cell surface markers. Following the recommendation
of the Fifth International Workshop on CLL, which re-
stricts the definition of B-CLL to cases expressing
CD5 (27), no cases of CD5-negative B-CLL were in-
cluded in this study. Moreover, all the cases were
CD23 positive. The presence of B cell derived mono-
clonal populations was demonstrated for all patients
based on immunophenotypic analysis of cell surface
immunoglobulins (SmIg) and immunogenotypic
analysis of immunoglobulin gene rearrangements.
For most cases, the fraction of malignant cells, iden-
tified by their CD19/CD5 expression, in the pathologi-
cal specimen was greater than 80% and in all cases
greater than 45%, as demonstrated by immunophe-
notypic analysis. For all cases a mononuclear cell
suspension of more than 95% viability was prepared
by Ficoll-Hypaque (Pharmacia, Piscataway, NJ) den-
sity gradient centrifugation.
DNA Extraction and Southern Blot
Analysis
Genomic DNA was prepared from mononuclear cell
suspensions by cell lysis, proteinase K digestion,
"isalting out" extraction, and ethanol precipitation as
described.28 For Southern blot analysis,29 6 ,g of
DNA was digested with the appropriate restriction en-
donuclease, electrophoresed in 0.8% agarose gel,
denatured, neutralized, transferred to Duralose filters
(Stratagene, La Jolla, CA), and hybridized to probes
that had been labeled with 32P by random primer ex-
tension.30 Filters were washed in 0.2x standard sa-
line citrate (SSC) (1 x SSC = 0.15 M NaCI + 0.015 M
sodium citrate)/0.5% sodium dodecyl sulfate (SDS)
for 2 hours at 60 C, and then autoradiographed using
intensifying screens (Quanta 111, Dupont).
DNA Probes
Immunoglobulin (Ig) gene rearrangement analysis
was performed using a JH probe (a gift of Dr. S. Kors-
meyer)31 on Hindlll, EcoRI, and BamHl digests. The
configuration of the BcI-2 locus was investigated
using probes pFL-1 and pFL-2 (a gift of Dr. M. L.
Cleary)32 on BamHI digests and probe pB16 (a gift of
Dr. Y. Tsujimoto)33 on Hindlil digests. The Bc/-l locus
was studied using probe MTC (probe a and probe b
a gift of Dr. Y. Tsujimoto)34 and probe p94PS (a gift of
Dr. T. C. Meeker;)35 on BcA, HindlIl, and EcoRI di-
gests. Loss of heterozygosity at 17p13, the site of the
p53 locus, was studied using the two highly polymor-
phic probes pYNZ22.1/D17S536 and p144-D6/
D17S3437 on Hinf l digests, as previously reported.38
Amplification of the MDM2 gene was tested using the
c14-2 probe (kind gift of Dr. B.Vogelstein) on EcoRI
digests as described.39 The presence of 6q deletions
was studied using two highly polymorphic cosmid
clones mapping to 6q27: CEB3/D6S132 and CEB4/
D6S133 (a gift of Dr. G. Vergnaud)40 on Haelll and
Pvull digests, respectively.
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Oligonucleotides, Single Strand
Conformation Polymorphism (SSCP)
Analysis, and Direct Sequencing of
Polymerase Chain Reactions (PCR)
Products
The oligonucleotides used to amplify sequences of
the p53 gene exons 5 through 9 have been previously
reported.22 SSCP analysis was modified from Orita et
al41 and performed as previously described.22 Se-
quencing reactions were performed as previously re-
ported.22
Results
Patient Characteristics
The panel of 100 B-CLL cases included in this study
was selected for being represenLttive of the various
clinical features of the disease. Patients were repre-
sentative of the different stages according to Rai
(stages 0 to IV): 18 cases were analyzed while in Rai's
stage 0, 35 in stage 1, 38 in stage 11, and 9 in stages
Ill and IV. The proliferative kinetics of the disease was
also taken into account and scored as LDT, which
represents an independent prognostic marker. LDT
was >36 months in 36 cases, 12 to 36 months in 19
cases, and < 12 months in 14 cases; in the other cases
LDT could not be evaluated and was indicated as 0.
Finally, for each Rai's stage and LDT value, the pa-
tients included were representative of different thera-
peutic statuses.
A
4,4%+qi
B
23 -23 -
9.4
6.6 -
4.4 -
9A -
6.6 -
4.4-
Overall, 49 cases had received treatment with
chlorambucil and prednisone, including 6/18 cases in
stage 0, 14/35 in stage 1, 21/38 in stage 11, and 8/9 in
stages III and IV, whereas the other 51 cases were
studied before onset of therapy. With respect to LDT,
9/12 cases with LDT <12 months, 14/19 with LDT 12
to 36 months, and 10/36 with LDT >36 months had
received chemotherapy. In all cases tested, a mono-
clonal pattern of Ig gene rearrangement was ob-
served by Southern blot analysis using a JH probe on
EcoRl, HincAll, or BamHI digestions (Figure 1). The
SmIg were weakly expressed in 98 cases (IgM/D
class in 69 cases, IgM alone in 24, and IgD alone in
5) and undetectable in 2 cases. In all patients, the
neoplastic lymphocytes co-expressed CD19 and
CD5 and were CD23 positive. Therefore, only "true"
B-CLL, as defined by the Fifth International Workshop
on CLL,17 were included in this study.
BCL- 1 and BCL-2 Studies
Chromosomal translocations involving chromosome
11q13, in the case of BcI-1, or chromosome 18q21,
in the case of BcI-2, and an antigen receptor locus
result in rearrangements of the Bc/-i and BcI-2 loci
observed in B cell neoplasia.8 9 In the case of BcI-2,
at least three breakpoint cluster regions have been
identified that can be explored by Southern blot
analysis using different DNA probes.3233 In the case
of Bc/-1, most cases rearrange within the major trans-
location cluster (MTC) region of the locus, although
sporadic breakpoints have also been found outside
C
: vVVV
23 -
9.4-
6.6-
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Figure 1. Immunogenotypic analysis (A), and molecular characterization ofBcl-l (B) and Bci-2 (C) in B-CLL. Genomic DNAs uwere digested u'ith
HindIII (A and C) or Bcl-l (B) and subjected to Southern hybridization using probes representative ofJH (A), the Bcl-l locus (probe a, B), and the
Bci-2 oncogene (probe pB16; C). U937 represents a germ line control for the Ig genes. All B-CLL cases, indicated by the letters LB followed by a
serial number, displayed a clonal rearrangement of the Ig genes. In all cases, Bcl-1 and Bcl -2 exhibited a germ line pattern.
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this cluster.3435 In this study, 100 cases of B-CLL
were subjected to Southern blot analysis using three
different probes each for the BcI-2 and Bc/-i loci on
multiple restriction endonuclease digests (Figure 1).
The BcI-2 probes used explored all three known trans-
location clusters, including the major cluster region
(MCR), the minor breakpoint region (MBR), and the
cluster region located in the 5' portion of the
gene.32,33 With respect to BcI-1, the MTC was ex-
plored with two probes, whereas a third probe tested
a breakpoint site located 5' of the MTC.34'35 No re-
arrangements of Bc/-i or BcI-2 were found in any of
the cases tested (Table 1).
The p53 Gene Inactivation
Inactivation of the p53 tumor suppressor gene in hu-
man tumors is most frequently caused by point mu-
tations in the coding sequence of exons 5 through 9
in one p53 allele with or without loss of the other wild-
type allele.42'43 In rare instances, mainly represented
by sarcomas, p53 inactivation occurs as a result of
amplification of the MDM2 gene, the product of which
inactivates p53 by binding to it.39 Both mechanisms
of p53 inactivation were assayed in the B-CLL cases
included in this study.
First, the occurrence of p53 mutations in B-CLL
was tested by a two-step strategy, as previously re-
ported.22 Exons 5 through 9 of the p53 gene were
analyzed in genomic DNA of 100 B-CLL cases by the
PCR-SSCP technique (Figure 2). Fragments display-
ing an altered electrophoretic mobility by SSCP
A
+ "I-0% , F, +4
analysis were then reamplified in a separate reaction
and analyzed by PCR direct sequencing to confirm
and characterize the mutation (Figure 2). Second,
MDM2 amplification was tested by Southern blot hy-
bridization.39
The p53 mutations were detected in 10% of B-CLL
cases (10/1 00; Table 1), whereas no patient showed
amplification of the MDM2 gene (data not shown).
Overall, p53 mutations were detected at all stages of
the disease, including 2/18 patients at stage 0, 2/35
at stage 1, 4/38 at stage 11, and 2/9 at stages III-IV. In
addition, mutations were detected both before che-
motherapy (2 cases) and after it (8 cases). LDT was
12 to 36 months in 3 of the patients harboring p53
mutations, <12 months in 1 case, and 0 in 6 cases.
The clinical features of the patients harboring p53 mu-
tations, together with the characteristics of the p53
mutation, are described in Table 2. Overall, the type
of lesion of p53 in B-CLL are similar to those found in
other lymphoid malignancies.22'43 The majority of mu-
tations (10/11 events) were represented by single
base pair substitutions, leading to a missense (9
cases) or a nonsense (1 case) mutation. One sample
displayed a point deletion.
In the majority of human tumors, p53 mutations are
accompanied by the deletion of the normal allele at
17p13, the site of the p53 locus.42'43 Therefore, we
tested the presence of loss of heterozygosity (LOH)
at 17p13 in B-CLL using two highly polymorphic
probes mapping to this region as previously re-
ported.38'44 LOH for 17p13 was detected in 6 of the
10 cases with a p53 gene mutation (Figure 3, Table 2).
Other Tumor Suppressor Loci
Recent molecular analysis of 6q- in B cell neoplasia
has shown that 6q deletions are a relatively frequent
event in some subsets of B cell malignancies, ie,
B-NHL, and that molecular analysis allows the de-
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Figure 2. Analysis by PCR-SSCP (A) and PCR direct sequencing (B) ofthep53 gene in B-CLL. A: PCR-SSCP. p53 exons 5 and 8 are shoun. Samples
were scored as positive when their migration pattern differed from the normal control (N). IM-6 and BL60 represetnt positive controls for exons 5
and 8. respectively (ref. 22). B: PCR direct sequencing: genomic sequence analysis zuas performedfor samples scored as positive by the PCR-SSCP
as-say to confirm and characterize the mutation. Cases LB1310 anid LB1251 are shown. CB3-3 represents a lymphoblastoid cell line used as wild-
type control. The coditng strands are shoun for both cases. Mutations are indicated by arrous; the codon at which the mutation occurs is also
shouwn.
Table 1. Frequency of Genetic Lesions in B-CLL
Bcl-1 * Bcl-2* p53* 6q*
Stage 0
Stage
Stage II
Stages Ill and IV
v T %,
T
EXONS
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Table 2. Summaty ofp53 Mutations in B-CLL
Patient Stage* LDTt Codon Mutation
Amino Acid
Substitution 17p13 LOH
LB1250 0 <12 179 CAT-CTT Hys-*Leu No
273 CGT-sGGT Arg-*Gly
LB1310 0 0 273 CGT-sCTT Arg-*Leu Yes
LB1304 12-36 234 TAC--TGC Tyr--Cys Yes
LB1261 12-36 154 GGC-AGC GlySer No
LB1221 II 12-36 283 CGCTGC Arg-sCys Yes
LB1219 II 0 136 CAA--CAzA Frameshift No
LB1303 II 0 175 CGC-CAC Arg-*Hys No
LB 1220 11 0 165 CAG->TAG Gln--Stop Yes
LB 1251 III-IV 0 275 TGTTGG Cys-*Trp Yes
LB1273 III-IV 0 175 CGCCAC Arg-*Hys Yes
Patients were staged according to Rai's staging system (ref. 3).
t LDT (ref.4). LDT was scored as follows: <12 months; 12 to 36 months; >36 months; 0, not evaluable.
A B
4A-
2.3-
2.0-
1.3
107-
0.60-
Figure 3. LOH analysis at 1 7p13 in representative B-CLL cases.
Genomic DNAs were digested uith Hinfl subjected to Southern blot
hybridization and probed with the highly polymorphic clones
pYNZ22.1 (A) and p144-D6 (B), mappinig to the vicinity of p53.
pYNZ22.1 recognizes one allelic system. The p144-D6 rcecognizes ttuo
allelic systems (a and b, identified by brackets on the side of the fig-
ure) and tu'o constant bands, one of uhich co-migrates with one of
the alleles of system a. Cases were scored as positive for LOH when
displaying only one allele in all three allelic systems, as previously re-
ported (refs. 38, 44). Among the cases shownt, LB1310 and LB1251
display onlv onie allelic band uwith both probes, indicating the pres-
ence of LOH. On the contrary, all the other cases, including the nor-
mal control (N) show two bands in all three) allelic systems. In the
case ofLB1310, LB1250, and LB1252 onie allele of the allelic system a
recognized by p144-D6 co-migrates with a contstant band.
tection of small 6q deletions undetectable at the cy-
togenetic level.45 These observations, coupled with
the lack of molecular studies of 6q in B-CLL,
prompted us to investigate the role of 6q- in this
disease. By using two highly polymorphic probes
(heterozygosity >90%) mapping within the region of
minimal deletion, the presence of a deletion can be
rapidly tested in the absence of paired normal
DNA.46 We therefore analyzed 100 cases of B-CLL
using the probes CEB3/D6S132 and CEB4/D6S133,
which recognize the presence of a deletion unde-
tectable at the cytogenetic level. A 6q deletion was
scored in 4/100 cases (Table 1), including 3 cases at
stage and 1 case at stage 11. LDT was >36 months
in 2 cases, <12 months in 1 case, and 0 in 1 case. All
cases harboring a 6q deletion
type p53 sequences.
displayed only wild-
Discussion
In this study we have performed a comprehensive
molecular analysis of the Bc/-i, Bcl-2, and p53 genes
and 6q deletions in 100 cases of B-CLL patients at
different stages of the disease. Following the recom-
mendations on the Fifth International Workshop on
CLL regarding the definition of "true" B-CLL,27 only
CD5+ CD23+ cases were included in this study. We
aimed to conclusively define the frequency of each
genetic lesion in a large panel of cases and testing the
association between the presence of a genetic le-
sions and the clinical behavior of the tumor.
No alterations of Bc/-i and Bcl-2 were detected in
our B-CLL panel. In this respect, our results are at
variance with previous studies that had detected re-
arrangements of these genes in a variable proportion
of cases.10-20 However, most Bc/-i- and/or Bcl-2-
positive cases reported in the literature displayed pe-
culiar phenotypic features inconsistent with a diag-
nosis of true B-CLL, according to the Fifth
International Workshop on CLL. Indeed, the Bc/-l-
and Bc/-2-positive cases reported by Raghoebier et
all1 lacked CD5 expression, whereas they expressed
the surface marker FMC-7, typically associated with
prolymphocytic leukemia. The Bc/-i-positive cases
described by Newman et a120 displayed atypical mor-
phology and surface expression of CD1 lb. Prolym-
phocytic features were observed in a Bc/-i-positive
case reported by Meeker et al16 Among the three Bcl-
2-positive cases reported by Adachi et al,12 only two
were known to express CD5 and, moreover, the ex-
pression of CD23 was not assessed in any of the
cases. Finally, the original B-CLL case from which
Bc/-i had been cloned was rediagnosed as centro-
4A -
23 -
2.0 -
1.3
1.0 -
0.87 -
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cytic lymphoma at a later examination of the
sample.47 Thus, our comprehensive analysis of Bc/-i
and BcI-2 in 100 cases of CD5+ CD23+ B-CLL rules
out that Bc/-i and Bcl-2 rearrangements play a role in
the pathogenesis of true B-CLL, and suggests that
cases originally found to harbor Bc/-l and Bcl-2 le-
sions may represent other lymphoproliferative disor-
ders biologically distinct from B-CLL.
Deletions of 6q have been regarded as a frequent
event in B cell neoplasia and it has been recently
shown that molecular assays are superior to conven-
tional cytogenetics in detecting these abnormali-
ties.45 Here we have tested the molecular occurrence
of 6q- in B-CLL. Our data indicate that 6q- are a rare
event in B-CLL when compared with other B cell ma-
lignancies such as B cell non-Hodgkin lymphoma or
acute lymphoblastic leukemia.9 A similar frequency of
6q abnormalities in B-CLL was also detected in a pre-
vious cytogenetic study.48
Among the genetic lesions analyzed in this study,
p53 represents the only gene found to be involved in
a significant proportion of cases (10%) of B-CLL. In-
activation of p53 is found at all stages of the disease,
suggesting that it may represent an early lesion at
least in some cases. Because p53 mutations are also
present in 50% of cases of Richter's syndrome,22 it
remains to be established whether B-CLL patients
harboring p53 mutations are more prone to develop
a Richter's syndrome or, conversely, whether p53 mu-
tations occur de novo during Richter's transformation.
In the case of tumor progression of other lymphoid
malignancies, ie, transformation of follicular lym-
phoma to diffuse lymphoma, p53 mutations are
thought to occur at the time of histological evolu-
tion.49'50 In the case of B-CLL, studies with sequential
samples of B-CLL and Richter's syndrome are re-
quired to clarify this issue. The mutational spectrum
of p53 mutations in B-CLL resembles the one re-
ported in the majority of human tumors, including
other types of B cell neoplasia.22 42'43 The frequent
occurrence of p53 mutations at CpG dinucleotides,
reported for most human tumors and confirmed here
also in the case of B-CLL, suggests that these mu-
tations occur spontaneously as DNA replication er-
rors in the majority of cases.43
Based on the data presented here, it is clear that
p53 inactivation may only partially account for the mo-
lecular pathogenesis of B-CLL. Trisomy 12 and de-
letions of 13q14, the most common cytogenetic ab-
normalities in B-CLL,5'6 are thought to harbor
oncogenes or tumor suppressor genes relevant for
B-CLL development. The frequency of these two le-
sions in B-CLL, together with their clinical usefulness
as prognostic indicators, warrant a systematic search
of the genes involved.
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